Merck price target lowered to $108 from $115 at Guggenheim

Guggenheim analyst Vamil Divan lowered the firm’s price target on Merck (MRK) to $108 from $115 and keeps a Buy rating on the shares after updating the firm’s model following the company’s Q1 earnings last week. The company reported “solid earnings with both sales and EPS surpassing our and consensus expectations,” but management maintained their FY25 reported sales guidance and lowered non-GAAP EPS guidance by 6 cents at the midpoint, the analyst noted.